The question "What do I make next?" lies at the heart of every Pharma R&D project. Yet in today's market, with increasing regulatory scrutiny, rising costs, and growing demands for "value," identifying the next game-changing therapeutic from thousands of potential candidates as quickly as possible is critical. However, physical experimentation alone is not enough for organizations to conquer this challenge.
In silico modeling tools offer a means for R&D teams to maximize the value of their research by augmenting physical experiments with model-based predictions. Using this enriched knowledge, scientists can make data-driven decisions of what small or large molecule to make and test next.
In this webinar, in silico modeling experts from Dassault Systèmes BIOVIA will discuss the future direction of drug design software, showcasing real world examples of the transformative benefits these tools offer. Join us to learn how BIOVIA can help better guide your project teams in their future decision making.
Adrian Stevens, PhD, MRSC CChem
Director Product Management Predictive Sciences
Adrian Stevens is Director of Product Management for Predictive Science Applications at Dassault Systèmes BIOVIA. Prior to joining BIOVIA in 2008, he spent more than 12 years working in the domain of computational chemistry and biology within the pharmaceutical industry. Dr. Stevens has published approximately 20 papers and is named on three patents.
- What is BIOVIA’s predictive science strategy?
- How we are going to combine in silico with the lab (V+R)?
- What are the key steps for moving to a model-first paradigm?
- Chief Operating Officer
- VP/Director/Manager of IT
- Scientist
- Applications Specialist
- Research Scientist
- Lab Manager
- Lab Analyst
- Computational Chemists
